Edition:
United Kingdom

XOMA Corp (XOMA.OQ)

XOMA.OQ on NASDAQ Stock Exchange Global Market

23.83USD
23 Apr 2018
Change (% chg)

$0.14 (+0.59%)
Prev Close
$23.69
Open
$23.76
Day's High
$24.25
Day's Low
$23.11
Volume
26,006
Avg. Vol
58,252
52-wk High
$37.25
52-wk Low
$5.86

Chart for

About

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA... (more)

Overall

Beta: 3.07
Market Cap(Mil.): $161.31
Shares Outstanding(Mil.): 7.60
Dividend: --
Yield (%): --

Financials

  XOMA.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -7.13 -- --
ROI: -481.50 1.58 14.38
ROE: -- 2.41 16.07

BRIEF-Xoma Corp Says Amended License And Purchase Agreement Entered With Rezolute In Dec 2017

* XOMA CORP SAYS ON MARCH 30, CO AMENDED LICENSE AGREEMENT AND PURCHASE AGREEMENT ENTERED INTO WITH REZOLUTE IN DEC 2017 - SEC FILING Source text: (https://bit.ly/2GCCEuu) Further company coverage:

05 Apr 2018

BRIEF-Xoma Corp Files For Mixed Shelf Of Up To $300 Million

* XOMA CORP FILES FOR MIXED SHELF OF UP TO $300 MILLION – SEC FILING‍​ Source text (http://bit.ly/2D8ZcQW) Further company coverage:

07 Mar 2018

BRIEF-Xoma Reports Q4 Loss Per Share $0.16

* XOMA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

07 Mar 2018

BRIEF-XOMA Announces Exclusive License Agreement For XOMA 358 With Rezolute Inc.

* XOMA ANNOUNCES EXCLUSIVE LICENSE AGREEMENT FOR XOMA 358 WITH REZOLUTE, INC.

07 Dec 2017

BRIEF-Xoma posts Q3 revenue of $36.2 million

* Qtrly diluted net income per share available to common stockholders $1.98 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

06 Nov 2017

Competitors

  Price Chg
Albireo Pharma Inc (ALBO.OQ) $32.98 -0.29

Earnings vs. Estimates